$RMD (ResMed Inc.)

$RMD {{ '2016-08-18T12:33:06+0000' | timeago}} • Announcement

$RMD said it has filed legal actions with the United States International Trade Commission, Southern District Court of California in San Diego, as well as courts in New Zealand and Germany, to stop the infringement of its patented technology by New Zealand-based medical device manufacturer Fisher & Paykel Healthcare.

$RMD {{ '2017-11-17T16:34:01+0000' | timeago}} • Announcement

$RMD elected accomplished healthcare executive Karen Drexler to its BoD. Also, Chris Roberts is retiring after serving on $RMD's Board for more than 25 years. Drexler's appointment and Roberts' retirement both took effect following the company's annual meeting of shareholders held Nov. 16.

$MDXG {{ '2017-11-17T16:16:27+0000' | timeago}} • Announcement

$MDXG reiterated its 4Q17 revenue outlook of $87-88MM. The company reiterated its 2017 revenue estimate of $320.6-321.6MM, gross margin forecast of 89-90%, and GAAP EPS guidance of $0.31-0.32.

$MMSI {{ '2017-11-16T17:40:51+0000' | timeago}} • Announcement

$MMSI signed purchase agreement with $BDX for divestment assets in connection with its proposed acquisition of $BCR$MMSI expects the acquisition to provide incremental annual revenues of $42-48MM, and adjusted gross margins for the subject product lines of 60-70%. $MMSI expects deal to provide $0.10-0.19 in adjusted EPS accretion in FY18.

$MMSI {{ '2017-11-16T17:37:46+0000' | timeago}} • Announcement

$MMSI signed an asset purchase agreement with $BDX to buy certain assets which $BDX proposes to sell in connection with its proposed acquisition of $BCR. $MMSI proposes to buy the Aspira Pleural Effusion Drainage Kits and the Aspira Peritoneal Drainage System currently marketed by $BCR. The purchase price is $100MM.

$CELG {{ '2017-11-16T14:30:32+0000' | timeago}} • Announcement

$CELG and its partner $BLUE reported that FDA granted Breakthrough Therapy Designation, which will expedite the review of the plasma cell cancer treating therapy. This was based on the preliminary data from the ongoing phase 1 study of the therapy. In March 2013, Celgene and Bluebird Bio entered into a strategic alliance in the field of oncology.

$RMD {{ '2017-11-13T19:41:35+0000' | timeago}} • Infographic

$RMD ResMed Inc Earnings AlphaGraphic: Q1 2018 Highlights

$XRAY {{ '2017-11-03T19:09:19+0000' | timeago}} • Infographic

$XRAY DENTSPLY SIRONA Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$MTD {{ '2017-11-02T21:41:33+0000' | timeago}} • Infographic

$MTD Mettler-Toledo International Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$CELG {{ '2017-10-31T16:07:34+0000' | timeago}} • Announcement

In a confidential license agreement, $CELG and $LCI enter into a settlement related to Celgene's Thalomid drug, which is used to treat the plasma cell cancer. This agreement allows Lannett to manufacture and market a generic thalidomide product in the US from Aug. 1, 2019, or earlier under certain circumstances.

$IDXX {{ '2017-10-31T14:30:33+0000' | timeago}} • Infographic

$IDXX IDEXX Laboratories, Inc. Earnings AlphaGraphic: Q3 2017 highlights

$CELG {{ '2017-10-30T23:17:02+0000' | timeago}} • Announcement

$CELG cut down its FY17 GAAP EPS outlook from $5.36-5.62 range to $4.78-5.19 range. For FY20, the drugmaker slashed its total net product sales target from the previous target of greater than $21Bil to $19-20Bil range and adjusted EPS target was reduced from the previous target of greater than $13 to greater than $12.50.

$CELG {{ '2017-10-30T22:55:16+0000' | timeago}} • Announcement

Despite higher profit and revenues in 3Q17, $CELG cut down its outlook for 2017 and 2020. Profit spiked nearly six times to $988MM or $1.21 per share, while revenue rose 10% to $3.29Bil. Product sales were up 11% to $3.28Bil, helped by the increase in sales of Revlimid, Pomalyst/Imnovid, Otezla and Abraxane drugs.

$SYK {{ '2017-10-27T11:50:44+0000' | timeago}} • Infographic

$SYK Stryker Corp. Earnings AlphaGraphic: Q3 2017 Highlights

$CELG {{ '2017-10-26T12:55:41+0000' | timeago}} • Infographic

$CELG Celgene Corp. Earnings AlphaGraphic: Q3 2017 Highlights

$ISRG {{ '2017-10-23T16:52:19+0000' | timeago}} • Webcast

$ISRG upped its FY17 procedure growth guidance range to 15% to 16% from prior estimate of 14% to 15% above the 753,000 procedures performed in 2016. In regards to system placements, although the proportion of 3Q17 systems placed under operating leases was slightly lower than 2Q17, the company continues to expect an upward trend for FY17.

$ISRG {{ '2017-10-23T16:49:27+0000' | timeago}} • Webcast

$ISRG continues to launch its da Vinci X systems in new regions, as it launched in nine countries during 3Q17 and anticipates adding four more in 4Q17. The company said that da Vinci Xi makes up roughly 75% of new placements, da Vinci X makes up approx. 10% of new placements in its limited early launch and with the balance made up by Si technology.

$CELG {{ '2017-10-20T12:40:12+0000' | timeago}} • Announcement

$CELG disclosed in an SEC filing that it expects to incur a pretax charge to earnings for 4Q17 in the range of $300-500MM ($0.27-0.45 per diluted share after tax) in connection with its decision to stop the two trials for Crohn's disease. Celgene also added that it would require to pay half of this charge in cash.

$ISRG {{ '2017-10-19T21:40:26+0000' | timeago}} • Announcement

Worldwide da Vinci procedures grew approx. 15% in 3Q17 as $ISRG shipped 169 da Vinci Surgical Systems during the quarter. With $TRXC already in its sight, Intuitive Surgical will also be eyeing $MDT with much more concern as Medtronic is set to roll out its surgical robot system next year.

$ISRG {{ '2017-10-19T21:22:14+0000' | timeago}} • Announcement

Amidst concern over an emerging competition for its da Vinci Surgical Systems, $ISRG posted its 3Q17 results where revenue increased 18% and profit grew 41%. Recently, the US FDA has shown the green light for $TRXC to market its Senhance Surgical Robotic System, the first system since 2010 to compete head-to-head against $ISRG's da Vinci system.

$CELG {{ '2017-10-19T21:12:44+0000' | timeago}} • Announcement

$CELG said that it will stop the two trials for treating the Crohn's disease (a chronic inflammatory bowel disease), following the recommendation of the Data Monitoring Committee. No safety signals were identified during a recent interim futility analysis. Celgene added that the third trial will not be initiated at this time.

Recent Transcripts

ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
CASM (Cas Medical Systems Inc)
Thursday, November 9 2017 - 3:00pm
XRAY (DENTSPLY International Inc.)
Friday, November 3 2017 - 12:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, November 2 2017 - 9:00pm
OMED (OncoMed Pharmaceuticals, Inc.)
Thursday, November 2 2017 - 8:30pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
MASI (Masimo Corporation)
Tuesday, October 31 2017 - 8:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, October 31 2017 - 12:30pm
MDXG (MiMedx Group, Inc.)
Friday, October 27 2017 - 2:30pm
SYK (Stryker Corporation)
Thursday, October 26 2017 - 8:30pm
RMD (ResMed Inc.)
Thursday, October 26 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm
MMSI (Merit Medical Systems, Inc.)
Wednesday, October 25 2017 - 9:00pm
CSII (Cardiovascular Systems Inc.)
Wednesday, October 25 2017 - 8:45pm
NUVA (NuVasive, Inc.)
Tuesday, October 24 2017 - 8:30pm
ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
NURO (NeuroMetrix Inc.)
Thursday, October 19 2017 - 12:00pm
MGCD (MGC Diagnostics Corporation)
Wednesday, September 6 2017 - 8:30pm

AlphaGraphics you may like